C
CHAMPIONS ONCOLOGY, INC.
CSBRCIK 0000771856NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)DelawareFY ends Apr 30
Period
FY 2025
Revenue
$56.94M
Net Income
$4.70M
Total Assets
$32.34M
Equity
$3.77M
Shares Out
13.89M
Op. Cash Flow
$7.39M
Business
CHAMPIONS ONCOLOGY, INC. is a technology-enabled research organization that creates computational and experimental platforms to support oncology drug discovery and development. It offers in vivo and ex vivo pharmacology studies using a proprietary Patient Derived Xenograft (PDX) TumorBank, a multi-omic Datacenter, bioinformatics analyses, data licenses, and the Lumin SaaS analytics platform. Its business comprises Translational Oncology Solutions research services, data licensing/SaaS, and a drug discovery and development division focused on targeted therapies, immuno-oncology and cell therapy. It serves pharmaceutical and biotechnology clients globally across North America, Europe and Asia through direct contracting and subscription licensing.
Summary from filing dated 2025-07-23
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Oncology revenue | 57 | 50 | 54 | 49 | 41 | |
| Cost of oncology revenue | 28 | 29 | 30 | 24 | 21 | |
| Research and development | 7 | 10 | 12 | 9 | 7 | |
| Sales and marketing | 8 | 7 | 7 | 6 | 6 | |
| General and administrative | 9 | 11 | 10 | 9 | 7 | |
| Loss on disposal of equipment | 293,000 | 435,000 | 0 | — | — | |
| Total costs and operating expenses | 52 | 58 | 59 | 49 | 41 | |
| Income (loss) from operations | 5 | −7 | −5 | 607,000 | 366,000 | |
| Other income, net | 73,000 | 48,000 | −11,000 | −24,000 | 71,000 | |
| Income (loss) before income tax expense | 5 | −7 | −5 | 583,000 | 437,000 | |
| Benefit for income tax | −75,000 | −32,000 | 68,000 | 35,000 | 75,000 | |
| Net income (loss) | 5 | −7 | −5 | 548,000 | 362,000 | |
| basic (in dollars per share) | 0.34 | −0.54 | −0.39 | 0.04 | 0.03 | |
| diluted (in dollars per share) | 0.33 | −0.54 | −0.39 | 0.04 | 0.02 | |
| basic (in shares) | 14 | 14 | 14 | 13 | 13 | |
| diluted (in shares) | 14 | 14 | 14 | 14 | 15 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Cash | 10 | 3 | 10 | 9 | 5 | |
| Accounts receivable, net | 11 | 10 | 8 | 10 | 7 | |
| Prepaid expenses and other current assets | 1 | 1 | 1 | 1 | 957,000 | |
| Total current assets | 22 | 14 | 19 | 20 | 13 | |
| Operating lease right-of-use assets, net | 5 | 6 | 7 | 8 | 9 | |
| Property and equipment, net | 4 | 6 | 7 | 7 | 6 | |
| Other long term assets | 185,000 | 185,000 | 15,000 | 15,000 | 15,000 | |
| Goodwill | 335,000 | 335,000 | 335,000 | 335,000 | 335,000 | |
| Total assets | 32 | 26 | 34 | 35 | 28 | |
| Accounts payable | 4 | 6 | 5 | 3 | 2 | |
| Accrued liabilities | 3 | 2 | 2 | 2 | 2 | |
| Current portion of operating lease liabilities | 1 | 1 | 1 | 1 | 818,000 | |
| Other current liabilities | 135,000 | 150,000 | 145,000 | — | — | |
| Deferred revenue | 15 | 12 | 13 | 11 | 6 | |
| Total current liabilities | 24 | 22 | 22 | 17 | 11 | |
| Non-current portion operating lease liabilities | 5 | 6 | 7 | 8 | 9 | |
| Other non-current liabilities | 85,000 | 401,000 | 551,000 | 391,000 | 181,000 | |
| Total liabilities | 29 | 28 | 30 | 26 | 20 | |
| Common stock, $.001 par value; 200,000,000 shares authorized; 13,897,503 and 13,714,099 shares issued; and 13,777,170 and 13,593,766 shares outstanding at April 30, 2025 and 2024, respectively | 14,000 | 14,000 | 14,000 | 14,000 | 13,000 | |
| Treasury Stock, at cost | −708,000 | −708,000 | −74,000 | 0 | — | |
| Additional paid-in capital | 84 | 83 | 82 | 81 | 80 | |
| Accumulated deficit | −80 | −85 | −77 | −72 | −73 | |
| Total stockholders' equity (deficiency) | 4 | −2 | 5 | 9 | 7 | |
| Total liabilities and stockholders' equity (deficiency) | 32 | 26 | 34 | 35 | 28 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 654,000 | 1 | 864,000 | 912,000 | 598,000 | |
| Depreciation and amortization expense | 2 | 2 | 2 | 2 | 1 | |
| Decrease in uncertain tax position | −181,000 | 0 | — | — | — | |
| Operating lease right-of-use assets | 1 | 1 | 952,000 | 786,000 | 398,000 | |
| Allowance and estimated credit losses | −272,000 | 476,000 | 195,000 | 292,000 | 49,000 | |
| Accounts receivable | −1 | −2 | 1 | −3 | −2 | |
| Prepaid expenses and other current assets | 144,000 | −167,000 | −184,000 | −187,000 | −572,000 | |
| Other long term assets | 0 | −169,000 | 0 | — | — | |
| Accounts payable | −2 | 465,000 | 2 | 974,000 | −1 | |
| Accrued liabilities | 395,000 | −109,000 | −145,000 | 183,000 | −316,000 | |
| Operating lease liabilities | −1 | −1 | −907,000 | −631,000 | −242,000 | |
| Deferred revenue | 3 | −683,000 | 2 | — | — | |
| Net cash provided by (used in) operating activities | 7 | −6 | 4 | 6 | −2 | |
| Purchase of property and equipment | −389,000 | −836,000 | −3 | −2 | −3 | |
| Net cash used in investing activities | −389,000 | −836,000 | −3 | −2 | −3 | |
| Proceeds from exercise of options | 320,000 | 253,000 | 85,000 | 207,000 | — | |
| Repurchases of common stock | 0 | −634,000 | −74,000 | 0 | — | |
| Finance lease payments | −150,000 | −146,000 | 0 | 0 | −174,000 | |
| Net cash provided by (used in) financing activities | 170,000 | −527,000 | 11,000 | 207,000 | 1 | |
| Increase (decrease) in cash | 7 | −8 | 1 | 4 | −4 | |
| Equipment purchased in accounts payable | 197,000 | 0 | — | — | 0 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro